Stages I–III Inoperable Endometrial Carcinoma: A Retrospective Analysis by the Gynaecological Cancer GEC-ESTRO Working Group of Patients Treated with External Beam Irradiation and 3D-Image Guided Brachytherapy

Author:

Rovirosa Ángeles12ORCID,Zhang Yaowen3,Tanderup Kari4,Ascaso Carlos12,Chargari Cyrus5,Van der Steen-Banasik Elzbieta6,Wojcieszek Piotr7,Stankiewicz Magdalena7ORCID,Najjari-Jamal Dina8,Hoskin Peter9,Han Kathy10,Segedin Barbara11ORCID,Potter Richard12,Van Limbergen Erik13

Affiliation:

1. Fonaments Clinics Dpt., Faculty of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain

2. Radiation Oncology Dpt., Hospital Clinic-Universitat de Barcelona, 08036 Barcelona, Spain

3. Cancer Center, Henan Provincial People’s Hospital, Zhengzhou 450003, China

4. Danish Center for Particle Therapy, Institute of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark

5. Radiation Oncology Dpt., Institut Gustave Roussy, 94805 Villejuif, France

6. Radiation Oncology Dpt., Radiotherapie Groep, 6815 AD Arnhem, The Netherlands

7. Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland

8. Institut Català d’Oncologia, l’Hospitalet de Llobregat, 08908 Barcelona, Spain

9. Mount Vernon Cancer Centre, Northwood, Middlesex HA6 2RN, UK

10. Radiation Oncology Dpt., Princess Margaret Hospital, University Health Network, Toronto, ON M5G 2M9, Canada

11. Radiation Oncology Department, Institute of Oncology Ljubljana, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia

12. Department of Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria

13. Radiation Oncology Dpt., University Hospital Gasthuisberg, 3000 Leuven, Belgium

Abstract

Background/Purpose: Analyse the outcomes of stages I–III inoperable endometrial cancer (IEC) patients treated with external-beam-irradiation (EBRT) and 3D-image-guided-brachytherapy (IGBT). Material and Methods: Medical records of IEC patients receiving EBRT + IGBT in eight European and one Canadian centres (2004–2019) were examined, including: pelvic ± para-aortic EBRT and lymph node boost; anaesthetic procedure, applicators, BT-planning imaging, clinical target volume (CTV), brachytherapy schedule, and EQD2 to the CTV(α/β=4.5Gy) and D2 cm3(α/β=3Gy) for organs at risk. Complications are evaluated using CTCAEv4 scores. The 2- and 5-year survival probability according to stages was estimated (cancer-specific survival (CSS), disease-free survival (DFS), local relapse-free survival (LRFS), loco-regional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS)). Statistics: descriptive analysis and the Kaplan–Meier method. Results: 103 patients (stages: I-44, II-14, III-44) were included. Median follow-up: 28 months (7–170). All patients received pelvic ± para-aortic EBRT. Median D90-EQD2(α/β=4.5) to the CTV:73.3 Gy (44.6–132.7), 69.9 Gy (44.7–87.9 and 75.2 Gy (55.1–97) in stages I, II, and III, respectively. Thirty patients presented relapse (stages: 10-I, 3-II, 17-III): 24 uterine (stages: 7-I, 3-II, 14-III), 15 nodal (stages: 4-I, 1-II, 10-III), and 23 distant (stages: 6-I, 2-II, 15-III). Five year CSS was 71.2% (stages: 82%-I-II and 56%-III) and DFS, LRFS, LRRFS, and DMFS were 55.5%, 59%, 72%, and 67.2%, respectively. Late G3-G4 complications (crude): 1.3% small bowel, 2.5% rectum, and 5% bladder. Conclusion: In stages I–III of the IEC, EBRT + IGBT offer good 2- and 5-year CSS of 88.7% and 71.2%, respectively, with the best outcomes in stages I–II. Prospective studies are needed to determine how better outcomes can be achieved.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3